Delivery Order 36F79720D0099-36C24525N0987
Award Date
9/12/25
Potential Completion Date
9/19/25
Potential Value
$13K
Federal Agency
Veterans Integrated Service Network 5
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Pittsburgh, PA 15275, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm-fixed price delivery order contract awarded by the Department of Veterans Affairs (VA) to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer and supplier. The contract, valued at $730,030.82, is for the delivery of the drug Jynarque (tolvaptan) to VA medical facilities across the country. Jynarque is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract is issued under the VA's Pharmaceuticals and Drugs Federal Supply...
This is a firm-fixed price delivery order awarded by the Veterans Health Administration (VHA), part of the U.S. Department of Veterans Affairs (VA), to Otsuka America Pharmaceutical Inc. The $13,168.39 contract is for the supply of Jynarque (tolvaptan) 90mg-30mg tablets, a medication used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract was issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and has an ultimate completion date of...
This federal contract award was issued by the Department of Veterans Affairs (VA) to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer and supplier. The contract, valued at $12,559.90, is for the delivery of the drug JYNARQUE (tolvaptan) in 90mg-30mg dosages. JYNARQUE is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract is a Delivery Order under Otsuka's existing Federal Supply Schedule (FSS) contract with the VA, which has a...
This federal contract award to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer, was issued by the U.S. Department of Veterans Affairs (VA) for the delivery of the prescription drug Jynarque (tolvaptan). The contract is a delivery order valued at $12,559.90 and has a completion date of November 13, 2024. Jynarque is used to treat autosomal dominant polycystic kidney disease and hyponatremia. Otsuka America Pharmaceutical holds two Indefinite Delivery Vehicles (IDVs)...
This federal contract award was made by the Department of Veterans Affairs (VA) to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer and supplier. The contract is for the delivery of the medication Jynarque (tolvaptan), which is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract is a Blanket Purchase Agreement (BPA) with a ceiling value of $113,303.91 and a period of performance from October 2020 to October 2021. It was awarded...
This is a firm-fixed price delivery order contract awarded by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer and supplier. The contract is for the provision of the medication JYNARQUE 90MG/30MG, which is used to treat kidney disorders, autosomal dominant polycystic kidney disease, and hyponatremia. The contract has a potential value of $12,559.90 and a completion date of May 10, 2024. It...
This is a $12,559.90 firm-fixed price delivery order contract awarded by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer and supplier, to provide the drug JYNARQUE 90MG/30MG. The contract is placed against Otsuka's $396 million Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB), which enables delivery of Jynarque, Tolvaptan, and other drug products to VA...
This federal contract award was made by the Department of Veterans Affairs (VA) to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer. The $13,168.39 firm-fixed price delivery order is for the supply of JYNARQUE 90MG-30MG, a drug used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract, which has an ultimate completion date of May 2, 2025, was awarded on April 30, 2025 under the Pharmaceuticals and Drugs Federal Supply Schedule...
This federal contract award was made by the Department of Veterans Affairs (VA) to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer based in Rockville, Maryland. The $13,168.39 firm-fixed-price delivery order is for the drug JYNARQUE (tolvaptan), which is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and does not utilize any set-aside...
This is a firm-fixed price delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Otsuka America Pharmaceutical Inc., a large pharmaceutical manufacturer, to supply the drug Jynarque (tolvaptan) in dosages of 90mg/30mg. The contract is valued at $13,168.39 and has an ultimate completion date of March 7, 2025. This delivery order is issued under Otsuka's $396 million Federal Supply Schedule contract for pharmaceuticals and hematology-related products with the VA, as well as a...